These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31572020)

  • 1. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.
    Papakitsou I; Vougiouklakis G; Elisaf MS; Filippatos TD
    Clin Pharmacol; 2019; 11():133-143. PubMed ID: 31572020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
    Cahn A; Raz I; Leiter LA; Mosenzon O; Murphy SA; Goodrich EL; Yanuv I; Rozenberg A; Bhatt DL; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Langkilde AM; Sabatine MS; Wiviott SD
    Diabetes Care; 2021 May; 44(5):1159-1167. PubMed ID: 33653824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.
    Fernandez-Fernandez B; Sarafidis P; Kanbay M; Navarro-González JF; Soler MJ; Górriz JL; Ortiz A
    Clin Kidney J; 2020 Oct; 13(5):728-733. PubMed ID: 33123352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapagliflozin in patients with type 2 diabetes mellitus.
    Filippatos TD; Liberopoulos EN; Elisaf MS
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.
    Bajaj HS; Raz I; Mosenzon O; Murphy SA; Rozenberg A; Yanuv I; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Sabatine MS; Wiviott SD; Cahn A
    Diabetes Obes Metab; 2020 Jul; 22(7):1122-1131. PubMed ID: 32090404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials.
    Zhai M; Du X; Liu C; Xu H
    Front Clin Diabetes Healthc; 2021; 2():703937. PubMed ID: 36994345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes.
    Hinnen D
    Ther Adv Endocrinol Metab; 2015 Jun; 6(3):92-102. PubMed ID: 26137213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial.
    Satirapoj B; Korkiatpitak P; Supasyndh O
    Clin Kidney J; 2019 Jun; 12(3):326-332. PubMed ID: 31198224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P
    Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.
    Fitchett DH
    Eur Endocrinol; 2018 Sep; 14(2):40-49. PubMed ID: 30349593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.
    John M; Gopinath D; Jagesh R
    Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin.
    Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Metab Syndr Obes; 2019; 12():2549-2557. PubMed ID: 31819580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
    Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):845-854. PubMed ID: 31495651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.